Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Long-term Study of JTE-061 Cream in Infants With Atopic Dermatitis
jRCT2031250138Phase 3Active, not recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tapinarof in atopic dermatitis (AD), sponsored by Shionogi & Co., Ltd. Primary endpoint: Proportion of subjects with ≥75% improvement in EASI score from baseline at Week 8. Started Jul 2025; status: active, not recruiting.
02
Drugs
tapinarof
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031250138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250138.